ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger ReShape to Sell its Assets to Affiliate of Biorad Medisys for $5.16 Million IRVINE, Calif. and CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (NASDAQ:RSLS), the premier physician-led weight loss and metabolic health-solutions company, and Vyome Therapeutics, Inc., a private clinical-stage company targeting immuno-inflammat ...

ReShape and Vyome, a Clinical Stage Specialty Pharmaceutical Company Working To Treat Immuno-Inflammatory Diseases of Unmet Need, to Combine in All-Stock Merger ReShape to Sell its Assets to Affiliate of Biorad Medisys for $5.16 Million IRVINE, Calif. and CAMBRIDGE, Mass., July 09, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, and Vyome Therapeutics, Inc., a private clinical-stage company targeting immuno-inflamma ...

Exhibit 99.1 ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 ...

财务数据和关键指标变化 - 公司2024年第一季度收入为1.9亿美元,较2023年同期下降15%或0.3亿美元,主要原因是销量下降,主要受到GLP-1药物的影响 [38] - 毛利润在2024年第一季度和2023年第一季度均为1.2亿美元,毛利率从2023年第一季度的54%提高到2024年第一季度的60%,主要由于公司在2023年末裁员导致相关成本下降 [40] - 销售和营销费用从2023年第一季度的2.2亿美元下降53%至1亿美元,主要是广告和营销费用下降0.7亿美元,以及薪酬相关费用下降0.5亿美元 [41] - 一般管理费用从2023年第一季度的4.2亿美元下降56%至1.9亿美元,主要是专业服务费用下降1.3亿美元,以及薪酬相关费用下降0.5亿美元 [42] - 研发费用在2024年第一季度为0.5亿美元,与2023年第一季度基本持平 [43] - 非GAAP调整后EBITDA亏损从2023年第一季度的5.3亿美元减少至2.1亿美元,主要由于持续降低整体运营成本 [44] - 公司在2024年第一季度末的净营运资本约为4.4亿美元,主要由于现金和现金等价物2.5亿美元以及应收账款1.6亿美元,且公司资产负债表上无债务 [45] 各条业务线数据和关键指标变化 - 公司的主要业务是Lap-Band手术,其中Lap-Band 2.0 FLEX新产品在2月份开始有首批手术,并获得了积极的外科医生反馈,预计将成为公司Lap-Band业务的增长动力 [25][26][29] - 公司正在努力获得Lap-Band 2.0 FLEX在加拿大和欧盟的监管批准,以拓展国际市场 [25] - 公司还通过培训外科医生和外科实习生来推广Lap-Band手术,为未来的Lap-Band业务发展奠定基础 [27] 各个市场数据和关键指标变化 - 公司目前仅在美国市场销售Lap-Band产品,正在努力拓展加拿大和欧盟市场 [25] - 公司通过与Hive Medical的合作,利用数字营销和患者参与平台,提高了患者预约量和质量,并降低了目标市场的获客成本 [23][24] 公司战略和发展方向及行业竞争 - 公司确立了三大战略支柱:1)提高股东价值和实现盈利;2)扩大产品组合和分销;3)通过M&A拓展业务 [17][47][49] - 公司大幅削减运营成本,预计2024年运营费用将较2023年减少55.4%,以投资于增长动力,如Lap-Band 2.0 FLEX的推广 [20][22][47] - 公司认为Lap-Band手术是一种安全、可调节和可逆的手术方式,在GLP-1药物使用受限的情况下,将成为一个有增长潜力的市场机会 [15][16][31][32] - 公司正积极寻求战略性和协同性的并购机会,以拓展产品组合,提高竞争力 [9][49] 管理层对经营环境和未来前景的评论 - 管理层认为,随着GLP-1受体激动剂在减肥治疗中的普及,消除了对肥胖和医疗干预的stigma,将带动对Lap-Band等手术的需求增加 [10][13][14][15] - 但GLP-1药物的局限性,如长期耐受性差、费用高昂等,将推动患者寻求Lap-Band等手术作为下一步的减重治疗 [14][15][16][31][32] - 管理层对Lap-Band 2.0 FLEX的市场前景持乐观态度,认为其将成为公司Lap-Band业务的增长动力 [25][26][29] - 管理层表示将继续优化营销策略,提高获客效率,并通过并购等方式拓展产品组合,以应对行业竞争 [47][49] 问答环节重要的提问和回答 无提问和回答内容

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 . RESHAPE LIFESCIENCES INC (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or othe ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark one) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 RESHAPE LIFESCIENCES INC. (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q3 2023 Earnings Conference Call November 8, 2023 5:00 PM ET Company Participants Michael Miller - Rx Communications Paul Hickey - President & Chief Executive Officer Caroline Apovian - Member-ReShape Scientific Advisory Tom Stankovich - Chief Financial Officer Conference Call Participants Anthony Vendetti - Maxim Group. Operator Good afternoon and thanks for joining the ReShape Lifesciences Third Quarter 2023 Conference Call. I would now like to turn the call over to ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 . RESHAPE LIFESCIENCES INC (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or ...

ReShape Lifesciences Inc. (NASDAQ:RSLS) Q2 2023 Earnings Conference Call August 7, 2023 5:00 PM ET Company Participants Michael Miller - Rx Communications, IR Paul Hickey - President and CEO Tom Stankovich - CFO Christine Ren-Fielding - Member, ReShape Scientific Advisory Board Conference Call Participants Anthony Vendetti - Maxim Operator Good afternoon, and thank you for joining the ReShape Lifesciences Second Quarter 2023 Conference Call. I would like to turn the call over to Michael Miller from Rx Comm ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number: 1-37897 . RESHAPE LIFESCIENCES INC (Exact name of registrant as specified in its charter) Delaware 26-1828101 (State or other ...